Whole genome sequencing

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

Retrieved on: 
Tuesday, April 30, 2024
University of Southern California, Efficacy, University, UCSD, Radiation, Resection, Regenerative medicine, HGG, TMZ, Doctor of Philosophy, RRV, GBM, WGS, Glioblastoma, Artificial intelligence, Depression, CIRM, UCSF, USC, Intravenous therapy, Neoplasm, Clinical trial, Medicine, SHROOM3, Whole genome sequencing, SAN, Medical imaging

We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.

Key Points: 
  • We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.
  • DB107 consists of two components: DB107–RRV (vocimagene amiretrorepvec) as a prodrug activator gene therapy and DB107–FC (extended-release 5–fluorocytosine [5–FC]) as an oral prodrug.
  • Retrospective analysis of an earlier randomized clinical trial in patients with recurrent HGG suggested improved overall survival in DGM7–positive patients treated with DB107.
  • "We are excited to conduct this novel trial which will be investigating several new approaches for the first time in patients with newly–diagnosed high–grade glioma.

BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's Fastest' Real-Time Genomic Software 'PanOmiQ'

Retrieved on: 
Tuesday, April 30, 2024
Irritable bowel syndrome, University, Transcriptome, Protein, AI, Metagenomics, Professor, Data format, Dubai World Trade Centre, Research, VCF, Artificial intelligence, Dysbiosis, Personalized medicine, Multiomics, DNA, Genome, Whole genome sequencing, Health, Biomarker, University of Patras, Genomics, Medicine, Quality of life, Longevity, IBS, Medical device

DUBAI, UAE, April 30, 2024 /PRNewswire/ -- BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human genome. With unparalleled speed, precision, and versatility, it promises to transform healthcare worldwide. The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.

Key Points: 
  • The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.
  • As the culmination of years of research and development, PanOmiQ stands as the world's fastest genomic analysis software to date.
  • "Turnaround time in genomic analysis is critical, and this is where PanOmiQ comes in with its unmatched speed and accuracy.
  • Please join us at the Precision Medicine Expo on May 9th, 2024, at the Dubai World Trade Centre, where BioAro will introduce PanOmiQ's groundbreaking capabilities.

Newborn Screening Emergency: Urgent Call for Action to Identify 10,000+ Undiagnosed Rare Diseases

Retrieved on: 
Monday, April 29, 2024
Public, Lymphoma, Congress, Genomics, NBS, Aircraft, DSM-IV codes, Health, Partnership, Research, BIO, Leukemia, Pandemic, Patient, Health policy, Exome, Global health, Mass spectrometry, Diagnosis, Drug development, Associate, Quality of life, Whole genome sequencing, Registry, Pharmaceutical industry

HERDON, Va., April 29, 2024 /PRNewswire-PRWeb/ -- A pressing need for a comprehensive approach to newborn screening (NBS) has prompted advocacy for a collaborative effort between the United States and India. With a recent report (1) finding that delayed diagnosis in rare disease can yield costs ranging from $86,000 to $500,000 per year, coupled with the fact that NBS can be the gateway to early diagnosis and improved outcomes for rare diseases, (2) experts suggest that an alliance between the two nations could pioneer advancements in global health. Dr. Harsha Rajasimha, the Founder of the Indo US Organization for Rare Diseases (IndoUSrare) explains the urgent need for better NBS in both the US and India, "Cross-border collaborations between the US and India is good for all patients with rare diseases globally. The early identification of patients with rare diseases, creation of patient registries, and databases, in India and other countries is an urgent need and pre-requisite to engage the rest of the world in research and global clinical trials."

Key Points: 
  • Most patients with rare diseases remain undiagnosed and unidentified for a long time, especially, in LMICs where newborn screening isn't mandated yet.
  • Newborn screening programs only screen for a small number of metabolic diseases relative to the 10,000+ rare diseases that are known today.
  • Identification of newborn babies with rare diseases can significantly boost the number of new patients identified with rare diseases.
  • The U.S. and India need to lead by example in the fight against rare diseases by advancing expanded NBS.

EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Retrieved on: 
Friday, May 3, 2024
University, Part, CMO, Federal republic, Research, Cancer, Federal Patent Court (Germany), Vaccine, Business, Webcast, BioNTech, District court, Whole genome sequencing, Vaccination, Public, WHO, Hearing loss, Cardiology, Animal, EP 1, Omicron, GSK, Systems biology, Workforce, Infection, Messenger, Federal court, Therapy, Data monitoring committee, Safety, Monroe Dunaway Anderson, CVAC, Justice, RNA, Astrocytoma, Motion, Human, CureVac, Pandemic, GMP, Sąd rejonowy, SARS-CoV-2, Business development, Epitope, MD, Acuitas Therapeutics, DSMB, Ageing, Patent, Patient, Neurology, Operating cost, H5N1, MD Anderson Cancer Center, PPA, Interim, MBA, Antigen, COVID-19, Amgen

ET / 3 p.m. CET

Key Points: 
  • ET / 3 p.m. CET
    TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2023 and provided a business update.
  • “We closed out 2023 on a sturdy footing and are poised to advance strongly through 2024 with strategic initiatives to make CureVac fit-for-purpose.
  • Thaminda Ramanayake was appointed to the CureVac Management Team as Chief Business Officer effective June 1, 2024.
  • Mr. Ramanayake joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company’s business development organization.

EQS-News: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Retrieved on: 
Friday, May 3, 2024
University, Cell, Monroe Dunaway Anderson, CVAC, Malignancy, MD, RNA, Vaccine, IND, CureVac, Patient, Collaboration, MD Anderson Cancer Center, Assistant, Messenger, Antigen, Evolution, Drug discovery, Therapy, Whole genome sequencing, Investigational New Drug

Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

Key Points: 
  • Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need
    MD Anderson responsible for leading initial Phase 1/2 studies; CureVac retains worldwide exclusive rights to late-stage development, commercialization, or partnering of cancer vaccine candidates
    TÜBINGEN, Germany/HOUSTON, Texas, USA – April 16, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
  • The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson’s expertise in cancer antigen discovery and validation, translational drug development, and clinical research.
  • The collaboration will focus on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need.
  • “We are excited for cancer vaccines to potentially emerge as an essential therapeutic tool in the future,” Shukla said.

ProPhase Labs Unveils Project ZenQ-AI

Retrieved on: 
Tuesday, April 16, 2024
Project, Cancer, Genomics, Whole genome sequencing, Safety, AI, Esophageal cancer, Nebula Genomics, Genetics, Machine learning, WGS, Doctor of Philosophy, DNA, SNP, Therapy, ADC, Marker beacon, Prophase, NVIDIA, Genome, EAC, Database, Diagnosis, CIO, Biomarker, Algorithm, Spacecraft, Medical device

Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (WGS) spanning more than 130 countries, and equivalent to roughly 150 million ancestry SNP-based tests. Whole Genome Sequencing (WGS) offers an exhaustive exploration of an individual’s entire DNA, capturing all three billion base pairs for a complete and detailed genetic blueprint. This comprehensive approach contrasts sharply with SNP tests, which target specific genetic variations at known locations, typically analyzing between 100,000 to 1 million specific points. With WGS providing up to 30,000 times more genetic data than SNP testing, our service delivers unparalleled precision in personalized medicine and genetic research, far beyond the scope of standard SNP testing. Along with the data gathered from the Company’s BE-Smart Test for esophageal adenocarcinoma (EAC), the platform is being utilized to create algorithms that identify possible antibody drug conjugate (ADC) candidates for new cancer therapeutics.

Key Points: 
  • Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI.
  • "The power of Project ZenQ-AI not only stems from cutting-edge AI technology, but also the vast and growing genomic database that we’ve curated and continue to grow," explained Ted Karkus, CEO at ProPhase Labs.
  • To support the computational demands of Project ZenQ-AI, ProPhase Labs is utilizing a dual-approach in technology.
  • ProPhase Labs invites collaboration from across the scientific and medical communities to join in this groundbreaking initiative.

Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing

Retrieved on: 
Thursday, April 11, 2024
B-ALL, OGM, RNA, WGS, Genetic variation, Doctor of Philosophy, Research, Leukemia, Bone marrow, Biomarker, Genomics, Whole genome sequencing, Cancer, SVS, SAN, Vaccine

The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.

Key Points: 
  • The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.
  • The study concluded that OGM together with WGS can potentially identify new therapeutic targets and improve personalized medicine in pediatric leukemia and other cancers by providing a more complete view of genome variation, including structural variation.
  • The study findings showed that, of the 3,075 total SVs detected in the B-ALL samples, 1,255 were uniquely detected by OGM.
  • The study also found that WGS detected 66 gene fusions, and that OGM was able to detect an additional 56 fusions that were missed by WGS.

Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights

Retrieved on: 
Thursday, April 25, 2024
Oncology, Data Management, Health, Technology, Genetics, Artificial Intelligence, Biotechnology, Cancer, Sequence, Genetic testing, Disease, Patient, Genome, Diagnosis, Whole genome sequencing, Genetic counseling

Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively.

Key Points: 
  • Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively.
  • The clinical use of whole genome sequencing has relatively been limited due to cost and technology barriers.
  • “This milestone solidifies our position as the whole-genome precision health leader.”
    Inocras Inc. (formerly Genome Insight, Inc) is a pioneering provider of whole genome sequencing and analytics services for cancer and rare diseases.
  • The company is dedicated to unlocking the potential of genomic data to enable precision health for everyone.

UK Biobank and DNAnexus Collaboration Earns Bio-IT World 2024 Innovative Best Practices Global Impact Award for 500,000 Whole Genomes Data Release

Retrieved on: 
Thursday, April 11, 2024
Data Management, Health, Technology, Networks, Research, Science, Biotechnology, Cloud, Volunteering, Pain, Doctor of Philosophy, Conference, Prostate cancer, Disease, Senior, Diet, UK Biobank, Hospital Records, Biobank, Database, Diagnosis, Drug development, Whole genome sequencing, Breast cancer, Kingdom of Poland, Medical imaging

DNAnexus, Inc. , the provider of the Precision Health Data Cloud, today announced that its ongoing collaboration with UK Biobank will be recognized with the 2024 Innovative Best Practices Global Impact Award at the upcoming Bio-IT World Conference and Expo.

Key Points: 
  • DNAnexus, Inc. , the provider of the Precision Health Data Cloud, today announced that its ongoing collaboration with UK Biobank will be recognized with the 2024 Innovative Best Practices Global Impact Award at the upcoming Bio-IT World Conference and Expo.
  • Researchers from around the world are using the data to drive discovery of new diagnostics, treatments, and cures.
  • More than 30,000 approved researchers from at least 90 countries have registered to use UK Biobank, the world’s most comprehensive source of biomedical data.
  • She will share more information on the 500,000 whole-genome data release on the UK Biobank Research Analysis Platform during a presentation starting at 10:50 am.

BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's Fastest' Real-Time Genomic Software 'PanOmiQ'

Retrieved on: 
Thursday, April 25, 2024
Irritable bowel syndrome, University, Transcriptome, Protein, AI, Metagenomics, Professor, Data format, Dubai World Trade Centre, AB, VCF, Research, Dysbiosis, Personalized medicine, Multiomics, Intelligence, DNA, Genome, Whole genome sequencing, Health, Biomarker, University of Patras, Genomics, Medicine, Quality of life, Longevity, IBS, Medical device

The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.

Key Points: 
  • The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.
  • As the culmination of years of research and development, PanOmiQ stands as the world's fastest genomic analysis software to date.
  • "Turnaround time in genomic analysis is critical, and this is where PanOmiQ comes in with its unmatched speed and accuracy.
  • Please join us at the Precision Medicine Expo on May 9th, 2024, at the Dubai World Trade Centre, where BioAro will introduce PanOmiQ's groundbreaking capabilities.